Opinion
Video
Robert Gabbay, MD, PhD, discusses research showing that early intervention with a recent FDA-approved therapy can delay the onset of type 1 diabetes by an average of 2-3 years.
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups